After the introducing of Human Papillomavirus (HPV) vaccines in 2006, real-world studies have demonstrated decreases in the prevalence of specific HPV types and reduced rates of cervical lesions and cancer in vaccinated populations, wrote the American Academy of Pediatrics (AAP).
On September 5, 2023, the AAP stated the accumulated safety data from extensive postmarketing surveillance and epidemiologic studies conducted from 2009 through 2021 across 13 countries have been consistent with the safety profile in clinical trials.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
